FDA is investigating the carcinogenic risk of ranitidine

                                                                                    INQUIRY

      Washington, Oct. 24 - a spokesman for the U.S. Food and Drug Administration said Thursday that it is investigating whether ranitidine can cause carcinogens in the body of drug users, so as to comprehensively assess the health risks it may pose. The agency previously said it was investigating whether such drugs may contain carcinogens due to pollution and other reasons.
Ranitidine is commonly known as "shanweide". It can effectively inhibit the secretion of gastric acid. It is commonly used in the treatment of gastric ulcer, reflux esophagitis and so on. It has been used for many years in the world.
Valisure, a well-known online drug retailer in the United States, reported to the FDA last month that it hoped the agency would recall Sanofi (46.38, 0.61, 1.33%) - Aventis group's sanweide and other ranitidine drugs, because a higher level of N-nitrosodimethylamine (NDMA) was detected in these drugs sold in the U.S. market.
According to the list of carcinogens listed by the International Cancer Research Institute affiliated to the World Health Organization, NDMA belongs to category 2A carcinogens, that is, the evidence for animal carcinogenesis is sufficient, and the evidence for human carcinogenesis is insufficient, which is considered to be possible for human carcinogenesis.


INQUIRY sales@hellerbearings.com
  • Details： FDA is investigating the carcinogenic risk of ranitidine

  • Like Model No.:

  • We cooperate with UPS,TNT,FEDEX,EMS,DHL,etc.They guarantee to meet your needs in terms of time and money,even if you need your FDA is investigating the carcinogenic risk of ranitidine bearing tomorrow morning (aka overnight or next day air) on your desk, 2, 3 days or more.Note to international customers, YES, we ship worldwide. INQUIRY -->

    Hot Model No.: